Literature DB >> 8626117

Overexpression of p53 is not a feature of ovarian granulosa cell tumors.

F S Liu1, E S Ho, C R Lai, J T Chen, R T Shih, C H Yang, C M Tsao.   

Abstract

The p53 tumor suppressor gene has been extensively studied in various human tumors including epithelial ovarian cancers. However, little is known about the expression of this gene in ovarian granulosa cell tumors, the most common histologic type of sex cord-stromal tumors. We investigated whether overexpression of the p53 gene product occurs in this specific ovarian tumor. Nineteen patients with ovarian granulosa cell tumors were recruited in this study. Immunohistochemical staining for the p53 protein with monoclonal antibody PAb 1801 was performed in the paraffin-embedded tissue of each case to screen for p53 overexpression. Among the 19 ovarian granulosa cell tumors, there was only one well-differentiated tumor found to have nuclear immunoreactivity in a small fraction of tumor cells. Polymerase chain reaction--single-stranded conformation polymorphism was used to study the tumor showing focal p53 positivity, but no mobility shift was noted from exon 4 through exon 9 of the p53 gene. On the basis of this observation, we propose that alteration of the p53 tumor suppressor gene is not a common finding in ovarian granulosa cell tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626117     DOI: 10.1006/gyno.1996.0095

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  The new molecular biology of granulosa cell tumors of the ovary.

Authors:  Nicolas Kalfa; Reiner A Veitia; Bérénice A Benayoun; Brigitte Boizet-Bonhoure; Charles Sultan
Journal:  Genome Med       Date:  2009-08-25       Impact factor: 11.117

2.  Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary.

Authors:  Hans-Ullrich Völker; Sabine Engert; Andreas Cramer; Melanie Schmidt; Ulrike Kämmerer; Hans-Konrad Müller-Hermelink; Stefan Gattenlöhner
Journal:  Diagn Pathol       Date:  2008-07-09       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.